Vertex Pharmaceuticals Inc (MIL:1VRTX)
€ 441.05 -2.05 (-0.46%) Market Cap: 112.08 Bil Enterprise Value: 107.49 Bil PE Ratio: 0 PB Ratio: 7.54 GF Score: 73/100

Vertex Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2023 / 04:15PM GMT
Jessica Macomber Fye
JPMorgan Chase & Co, Research Division - Analyst

Great. Good morning, everyone. Welcome. I'm Jess Fye. I'm a large cap biotech analyst at JPMorgan, and we're delighted to be continuing the conference this morning with Vertex. There's going to be a Q&A session right in this room after the company's presentation, so no need to switch rooms. There's going to be mic runners. So if you have a question, you want to raise your hand, you can do that. Alternatively, you can use the portal to fire me questions to an iPad up here, and I can ask them for you or you can just listen to my questions. But without any further ado, let me pass it over to the CEO of Vertex, Reshma Kewalramani, for the presentation.

Reshma Kewalramani
Vertex Pharmaceuticals Incorporated - CEO, President & Director

Well, good morning, everybody. Jess, thank you so much, and thank you to JPMorgan for hosting this. It is nice to be back in San Francisco in person and to do this live. Some housekeeping notes to start with. This slide has our safe harbor statement

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot